Tumor Microenvironment, Multispecifics, and Immunomodulation

• 5832 · PDF Development and utility of precision FISH/IF multiomic panel to elucidate T cell functionality in the tumor microenvironment Anushka Dikshit, Chandler Callaway, Sukhbir Lulla, Will Paces, Alan Busar, Sara Wells, Mandy Bell, Lauren Matelski, Sharel Figueredo, Lenka Sinik
• 5833 · PDF Therapeutic targeting of adhesion receptor GPR56 for the treatment of triple-negative breast cancer Yueh-Ming Shyu, Joan Jacob, Carla Godoy, Treena Chatterjee, Zhengdong Liang, Kendra S. Carmon
• 5834 · PDF Dual targeting GLI1 and EZH2 for treatment of invasive breast cancer Jer-Yen Yang, Chun Ju Chang, Yu-Wa Lai
• 5835 · PDF Treatment of pancreatic cancer cells with Tumor Treating Fields (TTFields) and KRAS inhibitors Hila Fishman, Lena Lifshitz, Helena Mumblat, Zeina Drawshy, Anat Klein-Goldberg, Yara Eid Mutlak, Hila Ene, Efrat Zemer-Tov, Tali Voloshin, Itai Tzchori, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
• 5836 Augmented antitumor activity of Tumor Treating Fields (TTFields) with anti-VEGFR and docetaxel treatment in a lung cancer mouse model Helena Mumblat, Yara Eid Mutlak, Yuval Shmueli, Ruslana Militsin, Catherine Tempel-Brami, Shay Cahal, Alexandra Volodin, Sara Jacobovitch, Martin Gabay, Itai Tzchori, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
• 5837 · PDF Tolvaptan as a potential anticancer and immunomodulatory treatment for triple-negative breast cancer Laura Naldi, Zhi Huang, Brionna King, Kimberly McCarter, Kelsey Gardiner, Alessandro Peri, Lucio Miele, Giulia Monticone
• 5838 · PDF QLS2401: A novel PSMA/STEAP1/CD3 tri-specific T-cell engager for the treatment of mCRPC Chenjun Tang, Langyong Mao, Jiaxin Yue, Moyan Hu, Shuyong Zhao, Hua Ying, Weikang Tao
• 5839 · PDF Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug Amanda R. Decker-Farrell, Stephen A. Sastra, Tetsuhiro Harimoto, Marie C. Hasselluhn, Carmine F. Palermo, Tanner C. Dalton, Llewelyn Levett, Edward R. Ballister, Michael A. Badgley, Tobias Janowitz, Tal Danino, Kenneth P. Olive
• 5840 The development of minocycline-loaded microparticles and injectable alginate scaffolds composites to prolong release for the treatment of glioblastoma Florestella Rivera, Dorina A. Madrid, Samantha C. Davila, Serenade Trevino, Jorge L. De Leon, Sebastian Flores, Sue Anne Chew
• 5841 · PDF Targeting type XI collagen to facilitate elimination of cancer-associated fibroblasts? Annika Hettich, Cecilie Bager, Morten Karsdal, Nicholas Willumsen
• 5842 Combined KRAS pathway inhibition and liposomal irinotecan treatment enhances tumor regression, attenuates desmoplasia, and augments T cell infiltration in pancreatic ductal adenocarcinoma Hari Krishnareddy Rachamala, Fang Wei, Debabrata Mukhopadhyay, Hani M. Babiker
• 5843 Beyond viability: Post treatment single cell and spatial transcriptomic profiling in mixtures of PRISM barcoded cancer cell lines Laura Doherty, Ashish B. George, Mustafa Kocak, Paul Lund, Andrew Kohlway, Andrew Boddicker, Ben Song, Carlos Ruiz Perez, Bryan Lajoie, Catarina D. Campbell, Matthew G. Rees, Jennifer A. Roth
• 5844 Novel inhibition of transcriptional cyclin-dependent kinases, CDK12/13, using CT7439 as a treatment for colorectal cancer with CDK12 upregulation Jason A. Somarelli, Wylie Katherine Watlington, Divya Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu
• 5845 · PDF BCG010, a potentially best-in-class NKG2A blocker for cancer treatment Yong Xie, Peiran Li, Huichao Liang, Tao Wang, Yanan Guo, Rongjing Zhang, Zhe Shao
• 5846 AVA6103 is a FAP-enabled pre|CISION ® peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activity Curtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Francis Wilson, Michelle Morrow
• 5848 Targeting phosphodiesterase 10A by ADT-030 normalizes the tumor immune microenvironment by inhibiting RAS-MAPK signaling in both cancer cells and myeloid-derived suppressor cells Gazi Md Yeashin, Ogacheko David Okoko, Yan Ye, Xin Wang, Khalda Fadlalla, Adam Keeton, Yulia Maxuitenko, Xi Chen, Lynn Hedrick, Huidong Shi, Gary A. Piazza, Gang Zhou
• 5849 · PDF Leveraging expression of tumor microenvironment GAGs to enhance platinum-based therapy in pancreatic adenocarcinoma Vashti L. Bandy, Erica Peterson, Praveen Bhoopathi, Arunima Punjala, Vignesh Vudatha, Dongyu Zhang, Ada Beaudin, Thomas M. Clausen, Jennifer Koblinski, Chunqing Guo, Larisa Litovchick, Nicholas Woods, Jose G. Trevino, Nicholas P. Farrell
• 5850 · PDF Novel platinum nanotherapeutics reprogram the tumor microenvironment to potentiate cancer immunotherapy Yongbin Liu, Xueying Ge, Busra Akay Hacan, Dongfang Yu, Junjun Zheng, Roderic I. Pettigrew, Ping-Ying Pan, Shu-Hsia Chen, Junhua Mai
• 5851 (Common-light-chain-antibody+nano-body) × multi-matrix-immunization platform facilitates the development of antitumor multispecific antibody drugs Yi Gu, Xinde Liu, Peng Li, Feng He, Feng Hao, JInying Ning
• 5852 A novel CD33 and TRAIL-R2 targeting bispecific antibody to treat relapsed/refractory acute myeloid leukemia Shiva Bhowmik, William Brady, Kaitlyn Ko, Sheng Cai, William Grossman, Naval Daver, Jonathan Gerber, Herbert Kim Lyerly
• 5853 Bispecific and biparatopic antibodies targeting tumor-specific Tn-glycoepitopes on MUC1 and MUC4 enable broad, selective tumor coverage in epithelial cancers Nisha Shrestha, Boris Klebanov, Aaron C. Groen, Constantine Theodoropulos, Hans H. Wandall
• 5855 NECTIN4×PD-L1 bispecific antibody-drug conjugate integrating checkpoint blockade and targeted cytotoxicity for urothelial carcinoma and lung squamous cell carcinoma Kyoung-Ho Pyo, Seong-Hyun Park, Dongsop Lee, Haneol Kim, Younggyu Kong, Younggeun Lee, Hojin Yeom, Sowon Aum, Sun Hee Park, Huijo Oh, Cheyeon Kim, Hyeonseok Jin, Aera Lee, Hojeong Hong, Ju Hwan Kim, Hyungseok Choi, Mi-Kyung Kim, Taedong Han
• 5856 Hanjugator camptothecin platform: Effective, low-toxicity design maximizing antibody functionality and delivering potential best-in-class EGFR/cMet bispecific antibody-drug conjugate Rui Liu, Ge Song, Yushi Chi, Lingli Zhang, Fan Yang, Junjie Zhang, Boqi Gu, Chencheng Han, Xiayan Zhang, Wan-jen Yang, Xiaomu Cheng, Xiaoling Yuan, Yi Zhang, Zhiliang Lv, Qian Zou, Huixin Yan, Chen Hu, Jijun Yuan
• 5857 LBL-054 TDC: A first-in-class CDH17 targeted T cell engager drug conjugate for the treatment of CDH17-positive gastrointestinal cancer Yang Ye, Yurong Qin, Xingxing Fang, Xiaoya Liu, Tingting Li, Chengze Ni, Peng Zhang, Chao Chu, Mi Ye, Huan Lin, Wanting Wang, Guojin Wu, Jianming Sun, Hui Yuwen, Yuanzhi Lv, Jing Guan, Min Chen, Yue Zhao, Jordan Zhu, Charles Cai, Xiao Huang, Xiaoqiang Kang, Hong Ling
• 5858 · PDF SCR-M030, an innovative and potential first-in-class trispecific T cell engager targeting PSMA and STEAP1 for mCRPC Changyan Chen, Yayuan Fu, Shumei You, Meijuan Gao, Kun Wang, Yi kuang, Chuanchuan Lu, Renhong Tang
• 5859 · PDF Novel T cell engager targeting CD3 and CDH17 for the treatment of solid tumors Mingkun Zhang, Yuqiang Xu, Jun Wang, Jing Zhao

在完整检索应用中浏览本分会场 →